Skip to main content
Top
Published in: Neurological Sciences 6/2017

01-06-2017 | Original Article

Serum uric acid levels and freezing of gait in Parkinson’s disease

Authors: Ruwei Ou, Bei Cao, Qianqian Wei, Yanbing Hou, Yaqian Xu, Wei Song, Bi Zhao, Huifang Shang

Published in: Neurological Sciences | Issue 6/2017

Login to get access

Abstract

Uric acid (UA) is a natural antioxidant and iron scavenger in the human body, which has been hypothesized to exert an anti-oxidative effect in Parkinson’s disease (PD). This study aimed to investigate the relationship between serum UA levels and freezing of gait (FOG) in PD. A total of 321 Chinese PD patients with fasting serum UA evaluated were included in the cross-sectional study. Demographics, clinical features, and therapeutic regimen were collected. The Unified PD Rating Scale (UPDRS) III and Hoehn and Yahr (H and Y) stage were used to evaluate the severity of disease, and the Frontal Assessment Battery (FAB) and Montreal Cognitive Assessment (MoCA) scales were used to assess the cognitive function. Patients with FOG showed lower proportion of male, longer disease duration, lower body mass index, lower concentrations of serum UA, higher total levodopa equivalent daily dosage, higher UPDRS III score, greater median H and Y stage, lower scores of FAB and MoCA, and higher frequencies of motor fluctuation, dyskinesia, falls, and festination compared to patients without FOG (P < 0.05). The binary logistic regression model indicated that high UPDRS III score (OR = 1.049, P < 0.001), fluctuation (OR = 2.677, P = 0.035), dyskinesia (OR = 6.294, P = 0.003), festination (OR = 3.948, P < 0.001), falls (OR = 7.528, P < 0.001), and low serum UA levels (OR = 0.990, P < 0.001) were associated with FOG. Our study suggests that low serum UA concentration is associated with the occurrence of FOG in PD.
Literature
1.
go back to reference Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78(11):6858–6862CrossRefPubMedPubMedCentral Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78(11):6858–6862CrossRefPubMedPubMedCentral
3.
go back to reference Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66(12):1460–1468. doi:10.1001/archneurol.2009.247 CrossRefPubMedPubMedCentral Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66(12):1460–1468. doi:10.​1001/​archneurol.​2009.​247 CrossRefPubMedPubMedCentral
5.
go back to reference Picillo M, Santangelo G, Moccia M, Erro R, Amboni M, Prestipino E, Longo K, Vitale C, Spina E, Orefice G, Barone P, Pellecchia MT (2016) Serum uric acid is associated with apathy in early, drug-naive Parkinson’s disease. J Neural Transm (Vienna) 123(4):371–377. doi:10.1007/s00702-015-1502-5 CrossRef Picillo M, Santangelo G, Moccia M, Erro R, Amboni M, Prestipino E, Longo K, Vitale C, Spina E, Orefice G, Barone P, Pellecchia MT (2016) Serum uric acid is associated with apathy in early, drug-naive Parkinson’s disease. J Neural Transm (Vienna) 123(4):371–377. doi:10.​1007/​s00702-015-1502-5 CrossRef
6.
7.
go back to reference Giladi N, Nieuwboer A (2008) Understanding and treating freezing of gait in parkinsonism, proposed working definition, and setting the stage. Mov Dis Off J Mov Dis Soc 23(Suppl 2):S423–S425. doi:10.1002/mds.21927 CrossRef Giladi N, Nieuwboer A (2008) Understanding and treating freezing of gait in parkinsonism, proposed working definition, and setting the stage. Mov Dis Off J Mov Dis Soc 23(Suppl 2):S423–S425. doi:10.​1002/​mds.​21927 CrossRef
8.
go back to reference Morris ME, Iansek R, Galna B (2008) Gait festination and freezing in Parkinson’s disease: pathogenesis and rehabilitation. Mov Dis Off J Mov Dis Soc 23(Suppl 2):S451–S460. doi:10.1002/mds.21974 CrossRef Morris ME, Iansek R, Galna B (2008) Gait festination and freezing in Parkinson’s disease: pathogenesis and rehabilitation. Mov Dis Off J Mov Dis Soc 23(Suppl 2):S451–S460. doi:10.​1002/​mds.​21974 CrossRef
9.
go back to reference Amboni M, Cozzolino A, Longo K, Picillo M, Barone P (2008) Freezing of gait and executive functions in patients with Parkinson’s disease. Mov Dis Off J Mov Dis Soc 23(3):395–400. doi:10.1002/mds.21850 CrossRef Amboni M, Cozzolino A, Longo K, Picillo M, Barone P (2008) Freezing of gait and executive functions in patients with Parkinson’s disease. Mov Dis Off J Mov Dis Soc 23(3):395–400. doi:10.​1002/​mds.​21850 CrossRef
10.
go back to reference Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRefPubMedPubMedCentral Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRefPubMedPubMedCentral
11.
go back to reference Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Dis Off J Mov Dis Soc 22(1):41–47. doi:10.1002/mds.21198 CrossRef Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Dis Off J Mov Dis Soc 22(1):41–47. doi:10.​1002/​mds.​21198 CrossRef
12.
13.
go back to reference Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a Frontal Assessment Battery at bedside. Neurology 55(11):1621–1626CrossRefPubMed Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a Frontal Assessment Battery at bedside. Neurology 55(11):1621–1626CrossRefPubMed
15.
go back to reference Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe WH, Stocchi F, Tolosa E (2009) Validation of the freezing of gait questionnaire in patients with Parkinson’s disease. Mov Disord 24(5):655–661. doi:10.1002/mds.21745 CrossRefPubMed Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe WH, Stocchi F, Tolosa E (2009) Validation of the freezing of gait questionnaire in patients with Parkinson’s disease. Mov Disord 24(5):655–661. doi:10.​1002/​mds.​21745 CrossRefPubMed
16.
go back to reference Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull 33(4):419–425CrossRefPubMed Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull 33(4):419–425CrossRefPubMed
17.
go back to reference Lolekha P, Wongwan P, Kulkantrakorn K (2015) Association between serum uric acid and motor subtypes of Parkinson’s disease. J Clin Neurosci Off J Neurosurg Soc Australas 22(8):1264–1267. doi:10.1016/j.jocn.2015.02.015 Lolekha P, Wongwan P, Kulkantrakorn K (2015) Association between serum uric acid and motor subtypes of Parkinson’s disease. J Clin Neurosci Off J Neurosurg Soc Australas 22(8):1264–1267. doi:10.​1016/​j.​jocn.​2015.​02.​015
18.
go back to reference Fukae J, Ishikawa K, Hatano T, Yoritaka A, Takanashi M, Shimo Y, Tsugawa J, Tsuboi Y, Hattori N (2014) Serum uric acid concentration is linked to wearing-off fluctuation in Japanese Parkinson’s disease patients. J Parkinsons Dis 4(3):499–505. doi:10.3233/jpd-140353 PubMed Fukae J, Ishikawa K, Hatano T, Yoritaka A, Takanashi M, Shimo Y, Tsugawa J, Tsuboi Y, Hattori N (2014) Serum uric acid concentration is linked to wearing-off fluctuation in Japanese Parkinson’s disease patients. J Parkinsons Dis 4(3):499–505. doi:10.​3233/​jpd-140353 PubMed
19.
go back to reference Moccia M, Picillo M, Erro R, Vitale C, Longo K, Amboni M, Santangelo G, Spina E, De Rosa A, De Michele G, Santoro L, Barone P, Pellecchia MT (2014) Is serum uric acid related to non-motor symptoms in de-novo Parkinson’s disease patients? Parkinsonism Relat Dis 20(7):772–775. doi:10.1016/j.parkreldis.2014.03.016 CrossRef Moccia M, Picillo M, Erro R, Vitale C, Longo K, Amboni M, Santangelo G, Spina E, De Rosa A, De Michele G, Santoro L, Barone P, Pellecchia MT (2014) Is serum uric acid related to non-motor symptoms in de-novo Parkinson’s disease patients? Parkinsonism Relat Dis 20(7):772–775. doi:10.​1016/​j.​parkreldis.​2014.​03.​016 CrossRef
20.
go back to reference Cao B, Guo X, Chen K, Song W, Huang R, Wei QQ, Zhao B, Shang HF (2013) Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population. J Neurol 260(10):2511–2515. doi:10.1007/s00415-013-7006-z CrossRefPubMed Cao B, Guo X, Chen K, Song W, Huang R, Wei QQ, Zhao B, Shang HF (2013) Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population. J Neurol 260(10):2511–2515. doi:10.​1007/​s00415-013-7006-z CrossRefPubMed
21.
go back to reference Oropesa-Ruiz JM, Huertas-Fernandez I, Jesus S, Caceres-Redondo MT, Vargas-Gonzalez L, Carrillo F, Carballo M, Gomez-Garre P, Mir P (2016) Low serum uric acid levels in progressive supranuclear palsy. Mov Dis Off J Mov Dis Soc 31(3):402–405. doi:10.1002/mds.26466 CrossRef Oropesa-Ruiz JM, Huertas-Fernandez I, Jesus S, Caceres-Redondo MT, Vargas-Gonzalez L, Carrillo F, Carballo M, Gomez-Garre P, Mir P (2016) Low serum uric acid levels in progressive supranuclear palsy. Mov Dis Off J Mov Dis Soc 31(3):402–405. doi:10.​1002/​mds.​26466 CrossRef
22.
go back to reference Sakuta H, Suzuki K, Miyamoto T, Miyamoto M, Numao A, Fujita H, Watanabe Y, Hirata K (2017) Serum uric acid levels in Parkinson’s disease and related disorders. Brain Behav 7(1):e00598. doi:10.1002/brb3.598 CrossRefPubMed Sakuta H, Suzuki K, Miyamoto T, Miyamoto M, Numao A, Fujita H, Watanabe Y, Hirata K (2017) Serum uric acid levels in Parkinson’s disease and related disorders. Brain Behav 7(1):e00598. doi:10.​1002/​brb3.​598 CrossRefPubMed
24.
go back to reference Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, Harrison DG, Fukai T (2002) Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 22(9):1402–1408CrossRefPubMed Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, Harrison DG, Fukai T (2002) Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 22(9):1402–1408CrossRefPubMed
25.
go back to reference Iravani MM, Haddon CO, Rose S (1067) Jenner P (2006) 3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor. Brain Res 1:256–262. doi:10.1016/j.brainres.2005.10.086 Iravani MM, Haddon CO, Rose S (1067) Jenner P (2006) 3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor. Brain Res 1:256–262. doi:10.​1016/​j.​brainres.​2005.​10.​086
26.
go back to reference Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P (1986) Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235(3):747–754CrossRefPubMedPubMedCentral Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P (1986) Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235(3):747–754CrossRefPubMedPubMedCentral
27.
go back to reference Jones DC, Gunasekar PG, Borowitz JL, Isom GE (2000) Dopamine-induced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. J Neurochem 74(6):2296–2304CrossRefPubMed Jones DC, Gunasekar PG, Borowitz JL, Isom GE (2000) Dopamine-induced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. J Neurochem 74(6):2296–2304CrossRefPubMed
28.
go back to reference Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 80(1):101–110CrossRefPubMed Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 80(1):101–110CrossRefPubMed
29.
go back to reference Facheris MF, Hicks AA, Minelli C, Hagenah JM, Kostic V, Campbell S, Hayward C, Volpato CB, Pattaro C, Vitart V, Wright A, Campbell H, Klein C, Pramstaller PP (2011) Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson’s disease. J Mol Neurosci MN 43(3):246–250. doi:10.1007/s12031-010-9409-y CrossRefPubMed Facheris MF, Hicks AA, Minelli C, Hagenah JM, Kostic V, Campbell S, Hayward C, Volpato CB, Pattaro C, Vitart V, Wright A, Campbell H, Klein C, Pramstaller PP (2011) Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson’s disease. J Mol Neurosci MN 43(3):246–250. doi:10.​1007/​s12031-010-9409-y CrossRefPubMed
30.
go back to reference Shine JM, Naismith SL, Lewis SJ (2011) The pathophysiological mechanisms underlying freezing of gait in Parkinson’s Disease. J Clin Neurosci Off J Neurosurg Soc Australas 18(9):1154–1157. doi:10.1016/j.jocn.2011.02.007 Shine JM, Naismith SL, Lewis SJ (2011) The pathophysiological mechanisms underlying freezing of gait in Parkinson’s Disease. J Clin Neurosci Off J Neurosurg Soc Australas 18(9):1154–1157. doi:10.​1016/​j.​jocn.​2011.​02.​007
32.
go back to reference Yogev-Seligmann G, Hausdorff JM, Giladi N (2008) The role of executive function and attention in gait. Mov Dis Off J Mov Dis Soc 23(3):329–342. doi:10.1002/mds.21720 (quiz 472) CrossRef Yogev-Seligmann G, Hausdorff JM, Giladi N (2008) The role of executive function and attention in gait. Mov Dis Off J Mov Dis Soc 23(3):329–342. doi:10.​1002/​mds.​21720 (quiz 472) CrossRef
Metadata
Title
Serum uric acid levels and freezing of gait in Parkinson’s disease
Authors
Ruwei Ou
Bei Cao
Qianqian Wei
Yanbing Hou
Yaqian Xu
Wei Song
Bi Zhao
Huifang Shang
Publication date
01-06-2017
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 6/2017
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-017-2871-3

Other articles of this Issue 6/2017

Neurological Sciences 6/2017 Go to the issue